SOMERSET, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Ventiv Health Inc. today announced that PharmaVOICE magazine named three Ventiv executives to its list of the 100 most inspiring business leaders.
The magazine’s list included Joy Morrell, president of Ventiv’s The Therapeutics Institute, Blane Walter, the chief executive of inChord Communications, the healthcare communications and marketing firm which Ventiv recently acquired, and Ed Mitzen, president of inChord’s Palio Communications subsidiary.
PharmaVOICE asked its readers to identify the people who they believe are having the greatest influence on corporate leadership, research and development, technology, creativity, marketing, and strategy. The PharmaVOICE 100 were selected based on the number of nominations received as well as on the quality of the write-ups that accompanied the submissions.
“Joy’s leadership of The Therapeutics Institute, which helps educate physicians about new medical technology and treatment paradigms, has helped Ventiv attain its leadership position in the market today and we’re very pleased to see her work and passion recognized,” said Eran Broshy, CEO of Ventiv Health. “At the same time, the inChord business and its superb management team is a major addition to Ventiv. We are delighted that Blane and Ed have been recognized by the industry, and look forward to their helping Ventiv further drive our leadership position in the pharmaceutical services marketplace.”
About Ventiv Health
Ventiv Health, Inc. is the leading provider of commercialization services to the global pharmaceutical and lifesciences industries. Ventiv delivers its customized clinical, sales, marketing and communications services through its three core business segments: Commercial Services, Clinical Services and Communications Services. Ventiv’s 4,600 employees support over 150 client organizations, including 18 of the Top 20 global pharmaceutical companies as well as emerging and specialty biotech leaders. For more information on Ventiv Health, Inc. visit www.ventiv.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health’s performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Health, Inc.
CONTACT: Investors, Corporate - John Emery, CFO, Ventiv Health, Inc.,+1-732-537-4804, investor@ventiv.com; or Media - Felicia Vonella,+1-212-843-0210, fvonella@lazarpartners.com, or Kellie Walsh,+1-646-871-8480, kwalsh@lazarpartners.com, both of Lazar Partners Ltd., forVentiv Health, Inc.
Web site: http://www.ventiv.com/
